Navigation Links
Haemacure Restructures - Seeks Financing or Sale of the Company
Date:2/13/2009

HAE:TSX

MONTREAL, Feb. 13 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE) announces that it has implemented cost-cutting measures in order to preserve cash. At the same time, the Company will continue to seek financing and will initiate a process intended to lead to a sale or merger of the Company.

Haemacure has been seeking financing since the third quarter of 2008. Several parties have expressed interest in an equity financing; however, this interest has not materialized into a viable financing. In light of the state of the financial markets, Haemacure believes that without operational changes its cash reserves will be exhausted before equity financing is completed, given Haemacure's operational burn rate and its previously-announced objective of getting into the clinic by mid-2009.

    Cost-Cutting Measures

    Haemacure has implemented the following measures, effective today:

    - 12 of Haemacure's 18 employees have been placed on leave in Montreal
      and Sarasota, Florida;
    - All major consulting agreements have been suspended;
    - Joseph Galli, Chairman & CEO, and Marc Paquin, President, will both
      continue to work with the Company for nominal compensation; and
    - The Company is undertaking measures with suppliers to restructure its
      obligations to them.

These restructuring measures provide the Company with a window of approximately 90 days in which to either arrange a bridge loan, obtain new financing, or to sell or merge the Company. As a result of these restructuring measures, and unless new financing is obtained, the Company will not commence the pivotal phase II/III clinical trials for its lead product candidate, an all-human fibrin sealant, as planned in mid-2009. However, the Company will continue, to the extent possible, with the preparation for these trials so that should funds become available the trials could commence without undue delay. A core team of manufacturing, quality and regulatory affairs and technical employees remains to preserve assets and support a potential sale or merger of the Company.

    Major Assets

    Haemacure's major assets are:

    - an operational state-of-the-art, cGMP-designed manufacturing facility
      in Sarasota, Florida for the production of fibrinogen and thrombin;
    - intellectual property allowing for low-cost and high-yield production
      of fibrinogen and thrombin;
    - an open IND with the U.S. Food and Drug Administration (FDA) pertaining
      to its all-human fibrin sealant which, assuming funding, would enter
      pivotal phase II/III clinical trials this summer; and
    - positive preclinical results on the use of its fibrin sealant for the
      prevention of the formation of postsurgical adhesion and for skin graft
      fixation for burn injuries.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development is focussed on the use of fibrin sealant in aesthetics, adhesion prevention, combination with biomaterials, drug delivery, regenerative medecine, skin graft fixation for burn injuries, and wound healing. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure is headquartered in Montreal, Canada and operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE Haemacure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure to Present at the 11th Annual BIO CEO & Investor Conference
2. Haemacure Announces Fiscal 2008 Results
3. Haemacures Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
4. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
5. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
6. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
7. Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
8. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
9. Haemacure to Present at the BioInternational Convention - The Global Event for Biotechnology - at the San Diego Convention Centre, California, from June 17 - 20, 2008
10. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
11. Haemacure Reports on Financing Progress and Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: